Xerosis of skin on background of anticancer therapy: Literature review and own experience with use of dermatocosmetics

Abstract

Xerosis is one of the most common dermatological side effects of anticancer drug therapy. The present observational study included 34 patients, among them 19 women, 15 men, mean age was 37.9 ± 3.5 years. All patients had skin xerosis, as well as various class-specific skin toxic reactions for drugs from the EGFR group (acne-like rash, paronychia, and others). With regard to skin toxic reactions, a thorough assessment of the severity was carried out and adequate therapy was prescribed in accordance with Russian clinical guidelines. In order to stop xerosis, all patients were recommended Lipikar Baume AP+М, Lipikar Syndet AP+, Cicaplast Baume B 5, Anthelios Invisible Fluid on an ongoing basis. As a result of observation (8 weeks), all patients noted the excellent organoleptic properties of La Roche-Posay products and the comfort of their use. All patients managed to control xerosis and other skin toxic reactions), none of the patients required dose reduction or withdrawal of anticancer therapy.